Impax regains rights to Parkinson's disease drug candidate

04/30/2013 | Reuters

Impax Laboratories will regain the rights to develop and market IPX066, an experimental Parkinson's disease drug, in certain countries after agreeing to end a collaboration deal with GlaxoSmithKline. The firms cited regulatory and commercialization delays in countries where GSK holds the right to sell the drug, known as Rytary in the U.S., as the reason for the deal's termination.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA
Senior Compliance Analyst
ACell, Inc.
Columbia, MD